NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
Clinical Trials
1 trialsCarcinoma, Intraductal, Noninfiltrating × Selective Estrogen Receptor Modulators × 90 days × Clear all